Neos Therapeutics Inc (NASDAQ:NEOS) Expected to Post Earnings of -$0.24 Per Share

Brokerages expect Neos Therapeutics Inc (NASDAQ:NEOS) to post ($0.24) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Neos Therapeutics’ earnings. Neos Therapeutics reported earnings per share of ($0.23) during the same quarter last year, which would suggest a negative year over year growth rate of 4.3%. The business is expected to announce its next quarterly earnings results on Thursday, March 12th.

On average, analysts expect that Neos Therapeutics will report full-year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.30). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.24) to ($0.15). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Neos Therapeutics.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Friday, November 8th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The company had revenue of $17.54 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%.

A number of research firms have recently issued reports on NEOS. ValuEngine raised shares of Neos Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. BMO Capital Markets reduced their price objective on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a research note on Monday, August 12th. Finally, Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 18th.

Several hedge funds and other institutional investors have recently made changes to their positions in NEOS. Alambic Investment Management L.P. lifted its position in Neos Therapeutics by 1,710.7% during the second quarter. Alambic Investment Management L.P. now owns 219,090 shares of the company’s stock valued at $283,000 after purchasing an additional 206,990 shares during the last quarter. Weiss Asset Management LP bought a new position in Neos Therapeutics during the second quarter valued at $36,000. Acadian Asset Management LLC bought a new position in Neos Therapeutics during the second quarter valued at $40,000. Paloma Partners Management Co bought a new position in Neos Therapeutics during the second quarter valued at $275,000. Finally, Jane Street Group LLC lifted its position in Neos Therapeutics by 332.1% during the second quarter. Jane Street Group LLC now owns 165,503 shares of the company’s stock valued at $213,000 after purchasing an additional 127,202 shares during the last quarter. 45.90% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:NEOS traded down $0.02 during midday trading on Friday, reaching $1.54. The company had a trading volume of 82,200 shares, compared to its average volume of 147,686. The company has a quick ratio of 0.91, a current ratio of 1.11 and a debt-to-equity ratio of 41.70. The business’s 50 day moving average price is $1.48 and its 200 day moving average price is $1.60. Neos Therapeutics has a 1-year low of $1.13 and a 1-year high of $3.62. The stock has a market cap of $77.58 million, a PE ratio of -0.96 and a beta of 0.93.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

See Also: Support Level

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.